Why is the development of vitiligo a predictor of good response in patients taking immunotherapy for melanoma, and what can scientists learn from this?
Triple wild-type melanoma may not respond to approved targeted drugs, but immunotherapy can be an excellent option.
In the fast-moving world of melanoma treatment, new therapeutic options for patients with metastatic disease are emerging faster than oncology researchers can establish guidelines for their optimal clinical use. That is raising questions about which should be the firstline choice in metastatic melanoma — targeted drugs or immunotherapy — and how these drugs should be sequenced.
Speech pathologists can help ease “chemobrain” through cognition training, and by teaching patients to compensate for deficits in memory or skills.
In clinical trials, melanoma remains a ripe discovery ground for the application and combination of immunotherapies and targeted drugs.